Browsing ICR Divisions by publication type "Other"
Now showing items 1-20 of 63
-
A Canadian approach to the regionalization of testis cancer: A review.
(2020-10)At the Canadian Testis Cancer Workshop, the rationale and feasibility of regionalization of testis cancer care were discussed. The two-day workshop involved urologists, medical and radiation oncologists, pathologists, ... -
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.
(2017-09)Purpose: To evaluate the safety, MTD, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TAK-117 (MLN1117/INK1117), an investigational PI3Kα-selective inhibitor, in patients with advanced solid tumors. ... -
A Multi-institutional Study of Risk Estimates Derived from Oncotype DX
(ELSEVIER SCIENCE LONDON, 2017-06-01) -
A Pilot Study: The Role of Radio-Opaque Hydrogel Tissue Marker in the Treatment of Postprostatectomy Intensity Modulated Radiation Therapy
(ELSEVIER SCIENCE INC, 2017-10-01) -
Adenoviral strategies for the gene therapy of cancer.
(2005-12)Despite slow clinical progress, efforts to develop specific nontoxic cancer gene therapies are increasing exponentially. Adenoviral vectors are one of the most popular vehicles for gene transfer currently being used in ... -
An intrinsically disordered proteins community for ELIXIR
(2019-10-15)Intrinsically disordered proteins (IDPs) and intrinsically disordered regions (IDRs) are now recognised as major determinants in cellular regulation. This white paper presents a roadmap for future e-infrastructure developments ... -
ART DECO (CRUK/10/018): dose escalated vs standard dose IMRT in locally advanced head and neck cancer
(ELSEVIER IRELAND LTD, 2017-03-01) -
BASELINE CIRCULATING TUMOR CELL COUNTS SIGNIFICANTLY ENHANCE A PROGNOSTIC SCORE FOR PATIENTS PARTICIPATING IN PHASE I ONCOLOGY TRIALS
(OXFORD UNIV PRESS, 2011-05-01) -
Chronic Lymphocytic Leukemia: New Concepts for Future Therapy
(CIG MEDIA GROUP, LP, 2010-10)Over the past several years, we have witnessed rapid advances in our understanding of the biology and treatment of chronic lymphocytic leukemia (CLL). New prognostic factors have been characterized that help identify ... -
Clinical Benefit from Vinorelbine after Prior Treatment with Eribulin: a Single-centre Experience
(ELSEVIER SCIENCE LONDON, 2017-06-01) -
Contribution of Common SNPs to Variability in Late Radiation Therapy Toxicity in Prostate Cancer
(ELSEVIER SCIENCE INC, 2017-10-01) -
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
(2017-04)Objective To evaluate the cost-effectiveness of adding zoledronic acid or strontium-89 to standard docetaxel chemotherapy for patients with castrate-refractory prostate cancer (CRPC).Patients and methods Data on resource ... -
COSTAR trial results: 3-D Conformal Radiotherapy vs Cochlea-Sparing IMRT in parotid cancer patients
(ELSEVIER IRELAND LTD, 2017-03-01) -
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine
(BIOMED CENTRAL LTD, 2014)The presence of multiple subclones within tumors mandates understanding of longitudinal and spatial subclonal dynamics. Resolving the spatial and temporal heterogeneity of subclones with cancer driver events may offer ... -
Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker.
(2019-11)Background Treatment of advanced epithelial ovarian cancer results in a relapse rate of 75%. Early markers of response would enable optimization of management and improved outcome in both primary and recurrent disease. ... -
Editorial on the Special Issue of Applied Sciences on the Topic of Elastography
(MDPI, 2018-08-01)
